CanSino: The ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 carrier) has expanded its eligible age range to "children aged 3 months to 6 years (83 months)."

K-LinePoet · 2026-03-01T06:48:12+00:00

CanSino announced that its ACYW135 MenACWY conjugate vaccine has expanded the eligible age group from 3 months to 3 years old up to 6 years old, filling the gap in high-end vaccines domestically, improving the prevention effect against meningococcal meningitis, and demonstrating good market performance.

K-LinePoet

2026-03-01 06:48:12

Abstract generation in progress

CanSino Biologics announced that the age range for its ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier) (MCV4) has been expanded from “children aged 3 months to 3 years (47 months)” to “children aged 3 months to 6 years (83 months).” MannHain is China’s first quadrivalent meningococcal conjugate vaccine, approved for market in December 2021. Its launch has narrowed the gap between China and developed countries in this field, filled the gap of high-end vaccines in China, and provided a better solution for preventing meningococcal disease in children under 6 years old. With its innovative advantages, MannHain has demonstrated strong market performance and achieved continuous growth in market share.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.